Diana Bracco: “we put people at the heart of sustainable development” During the conference "Sustainability, growth, employment: the Torviscosa model,” the Bracco Group presented its new Sustainability Report. The Report enumerates all the actions that Bracco, global leader in diagnostic imaging, has taken in favour of people, the planet and innovation.

Bracco announces long term strategic partnership with ulrich medical The partnership will bring a Bracco branded state of the art MR injector to the United States under an exclusive private label arrangement.

Mehr Transparenz, mehr Service Entdecken Sie die neue Service-Website www.gesundheitspolitik-bracco.de, die über Wissenswertes aus der bildgebenden Diagnostik informiert.

The EC granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union Vueway®, a new macrocyclic gadolinium-based contrast agent for CE-MRI, received Marketing Authorisation in the European Union By European Commission.

Europäische Kommission erteilt Marktzulassung für Vueway® (Gadopiclenol) Die Europäische Kommission hat am 7. Dezember 2023 die Marktzulassung für das MR-Kontrastmittel Vueway® (Gadopiclenol) von Bracco Imaging S.p.A. erteilt.

Vueway® (Gadopiclenol) Vueway® (Gadopiclenol) ist ein hochstabiles makrozyklisches MRT Kontrastmittel. Finden Sie weitere Fachinformationen auf dieser Seite.

Bracco @ ECR

The future in MRI: Vueway® Erfahren Sie mehr über das innovative MRT-Kontrastmittel Vueway® und über die ersten Erfahrungen in der täglichen Anwendung.

Samsung Medison and Bracco Imaging announce a new agreement Samsung Medison and Bracco Imaging endorsed a Memorandum of Understanding agreement to pioneer a new area for diagnostic ultrasound device and contrast agent at European Congress of Radiology 2024 held in Vienna, Austria on February 28th to March 3rd.

Ulm-Augsburger Radiologisches Sommer-Symposium